Lithium salts as a treatment for COVID-19 : Pre-clinical outcomes
Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved..
INTRODUCTION: Identifying effective drugs for Coronavirus disease 2019 (COVID-19) is urgently needed. An efficient approach is to evaluate whether existing approved drugs have anti-SARS-CoV-2 effects. The antiviral properties of lithium salts have been studied for many years. Their anti-inflammatory and immune-potentiating effects result from the inhibition of glycogen synthase kinase-3.
AIMS: To obtain pre-clinical evidence on the safety and therapeutic effects of lithium salts in the treatment of COVID-19.
RESULTS: Six different concentrations of lithium, ranging 2-12 mmol/L, were evaluated. Lithium inhibited the replication of SARS-CoV-2 virus in a dose-dependent manner with an IC50 value of 4 mmol/L. Lithium-treated wells showed a significantly higher percentage of monolayer conservation than viral control, particularly at concentrations higher than 6 mmol/L, verified through microscopic observation, the neutral red assay, and the determination of N protein in the supernatants of treated wells. Hamsters treated with lithium showed less intense disease with fewer signs. No lithium-related mortality or overt signs of toxicity were observed during the experiment. A trend of decreasing viral load in nasopharyngeal swabs and lungs was observed in treated hamsters compared to controls.
CONCLUSIONS: These results provide pre-clinical evidence of the antiviral and immunotherapeutic effects of lithium against SARS-CoV-2, which supports an advance to clinical trials on COVID-19's patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:149 |
|---|---|
| Enthalten in: |
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 149(2022) vom: 01. Mai, Seite 112872 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Soriano-Torres, O [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9FN79X2M3F |
|---|
| Anmerkungen: |
Date Completed 27.04.2022 Date Revised 19.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.biopha.2022.112872 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338942904 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338942904 | ||
| 003 | DE-627 | ||
| 005 | 20231226001812.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biopha.2022.112872 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1129.xml |
| 035 | |a (DE-627)NLM338942904 | ||
| 035 | |a (NLM)35364381 | ||
| 035 | |a (PII)S0753-3322(22)00261-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Soriano-Torres, O |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lithium salts as a treatment for COVID-19 |b Pre-clinical outcomes |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.04.2022 | ||
| 500 | |a Date Revised 19.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved. | ||
| 520 | |a INTRODUCTION: Identifying effective drugs for Coronavirus disease 2019 (COVID-19) is urgently needed. An efficient approach is to evaluate whether existing approved drugs have anti-SARS-CoV-2 effects. The antiviral properties of lithium salts have been studied for many years. Their anti-inflammatory and immune-potentiating effects result from the inhibition of glycogen synthase kinase-3 | ||
| 520 | |a AIMS: To obtain pre-clinical evidence on the safety and therapeutic effects of lithium salts in the treatment of COVID-19 | ||
| 520 | |a RESULTS: Six different concentrations of lithium, ranging 2-12 mmol/L, were evaluated. Lithium inhibited the replication of SARS-CoV-2 virus in a dose-dependent manner with an IC50 value of 4 mmol/L. Lithium-treated wells showed a significantly higher percentage of monolayer conservation than viral control, particularly at concentrations higher than 6 mmol/L, verified through microscopic observation, the neutral red assay, and the determination of N protein in the supernatants of treated wells. Hamsters treated with lithium showed less intense disease with fewer signs. No lithium-related mortality or overt signs of toxicity were observed during the experiment. A trend of decreasing viral load in nasopharyngeal swabs and lungs was observed in treated hamsters compared to controls | ||
| 520 | |a CONCLUSIONS: These results provide pre-clinical evidence of the antiviral and immunotherapeutic effects of lithium against SARS-CoV-2, which supports an advance to clinical trials on COVID-19's patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Lithium | |
| 650 | 4 | |a Pre-clinical trial | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Salts |2 NLM | |
| 650 | 7 | |a Lithium |2 NLM | |
| 650 | 7 | |a 9FN79X2M3F |2 NLM | |
| 700 | 1 | |a Noa Romero, E |e verfasserin |4 aut | |
| 700 | 1 | |a González Sosa, N L |e verfasserin |4 aut | |
| 700 | 1 | |a Enríquez Puertas, J M |e verfasserin |4 aut | |
| 700 | 1 | |a Fragas Quintero, A |e verfasserin |4 aut | |
| 700 | 1 | |a García Montero, M |e verfasserin |4 aut | |
| 700 | 1 | |a Martín Alfonso, D |e verfasserin |4 aut | |
| 700 | 1 | |a Infante Hernández, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Lastre, M |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Pérez, L |e verfasserin |4 aut | |
| 700 | 1 | |a Borrego, Y |e verfasserin |4 aut | |
| 700 | 1 | |a González, V E |e verfasserin |4 aut | |
| 700 | 1 | |a Vega, I G |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos Pupo, R |e verfasserin |4 aut | |
| 700 | 1 | |a Reyes, L M |e verfasserin |4 aut | |
| 700 | 1 | |a Zumeta Dubé, M T |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández, Amaro |c 1st |e verfasserin |4 aut | |
| 700 | 1 | |a García de la Rosa, I |e verfasserin |4 aut | |
| 700 | 1 | |a Minguez Suárez, A |e verfasserin |4 aut | |
| 700 | 1 | |a Alarcón Camejo, L A |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez, M |e verfasserin |4 aut | |
| 700 | 1 | |a Oliva Hernández, R |e verfasserin |4 aut | |
| 700 | 1 | |a Rudd, C E |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez, O |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie |d 1984 |g 149(2022) vom: 01. Mai, Seite 112872 |w (DE-627)NLM012645591 |x 1950-6007 |7 nnns |
| 773 | 1 | 8 | |g volume:149 |g year:2022 |g day:01 |g month:05 |g pages:112872 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.biopha.2022.112872 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 149 |j 2022 |b 01 |c 05 |h 112872 | ||